Similar molecular descriptors determine the in vitro drug permeability in endothelial and epithelial cells

International Journal of Pharmaceutics

Volumn 436, Issue 1-2, 2012, Pages 426-443

  Hakkarainen, Jenni J ^a   Pajander, Jari ^a   Laitinen, Riikka ^a   Suhonen, Marjukka ^a   Forsberg, Markus M ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

BBMEC; Blood brain barrier; In vitro permeability; Principal component analysis

Indexed keywords

1 [1 (4 PHENYLBUTANOYL)PYRROLIDINE 2 CARBONYL]PYRROLIDINE 2 CARBONITRILE; ACICLOVIR; ALLOPURINOL; ALPRENOLOL; ATENOLOL; BACLOFEN; CEFALEXIN; CYCLOSPORIN A; DIAZEPAM; DIGOXIN; ENTACAPONE; IBUPROFEN; KYP 2047; METOPROLOL; METRONIDAZOLE; MIDAZOLAM; N BENZYL 2 [[2 (HYDROXYACETYL) 1 PYRROLIDINYL]CARBONYL] 1 PYRROLIDINECARBOXAMIDE; ONDANSETRON; PARACETAMOL; PHENAZONE; PINDOLOL; PROPRANOLOL; PYRROLIDINE DERIVATIVE; SUCROSE; THEOPHYLLINE; TOLCAPONE; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; CELL PERMEABILIZATION; COW; DRUG PENETRATION; ENDOTHELIUM CELL; EPITHELIUM CELL; HYDROGEN BOND; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MICROVASCULATURE; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; PASSIVE TRANSPORT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CACO-2 CELLS; CATTLE; CELL LINE; CELLS, CULTURED; DOGS; ENDOTHELIAL CELLS; EPITHELIAL CELLS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MADIN DARBY CANINE KIDNEY CELLS; MOLECULAR CONFORMATION; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PRINCIPAL COMPONENT ANALYSIS; PROTEASE INHIBITORS;

EID: 84865280295     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.06.049     Document Type: Article

References (47)

1. N.J. Abbott Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro and in silico models Drug Discov. Today: Technol. 1 2004 407 416 10.1016/j.ddtec.2004.11.014
2. C.J. Bachmeier, W.J. Trickler, and D.W. Miller Comparison of drug efflux transport kinetics in various blood-brain barrier models Drug Metab. Dispos. 34 2006 998 1003 10.1124/dmd.105.006999
3. G.W. Caldwell, Z. Yan, W. Tang, M. Dasgupta, and B. Hasting ADME optimization and toxicity assessment in early- and late-phase drug discovery Curr. Top. Med. Chem. 9 2009 965 980
4. E.C. Chan, W.L. Tan, P.C. Ho, and L.J. Fang Modeling Caco-2 permeability of drugs using immobilized artificial membrane chromatography and physicochemical descriptors J. Chromatogr. A 1072 2005 159 168 10.1016/j.chroma.2005.03.006
5. L.L. Chen, J. Yao, J.B. Yang, and J. Yang Predicting MDCK cell permeation coefficients of organic molecules using membrane-interaction QSAR analysis Acta Pharmacol. Sin. 26 2005 1322 1333 10.1111/j.1745-7254.2005.00166.x
6. M.P. Dehouck, P. Jolliet-Riant, F. Bree, J.C. Fruchart, R. Cecchelli, and J.P. Tillement Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models J. Neurochem. 58 1992 1790 1797
7. A. Di Fenza, G. Alagona, C. Ghio, R. Leonardi, A. Giolitti, and A. Madami Caco-2 cell permeability modelling: a neural network coupled genetic algorithm approach J. Comput. Aided Mol. Des. 21 2007 207 221 10.1007/s10822-006-9098-3
8. E.P. Eddy, B.E. Maleef, T.K. Hart, and P.L. Smith In vitro models to predict blood-brain barrier permeability Adv. Drug Deliv. Rev. 23 1997 185 198 10.1016/S0169-409X(96)00435-8
9. P. Ertl, B. Rohde, and P. Selzer Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties J. Med. Chem. 43 2000 3714 3717 10.1021/jm000942e
10. F. Faassen, G. Vogel, H. Spanings, and H. Vromans Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs Int. J. Pharm. 263 2003 113 122 10.1016/S0378-5173(03)00372-7
11. H. Franke, H. Galla, and C.T. Beuckmann Primary cultures of brain microvessel endothelial cells: a valid and flexible model to study drug transport through the blood-brain barrier in vitro Brain Res. Brain Res. Protoc. 5 2000 248 256 10.1016/S1385-299X(00)00020-9
12. P. Garberg, M. Ball, N. Borg, R. Cecchelli, L. Fenart, R.D. Hurst, T. Lindmark, A. Mabondzo, J.E. Nilsson, T.J. Raub, D. Stanimirovic, T. Terasaki, J.O. Öberg, and T. Österberg In vitro models for the blood-brain barrier Toxicol. In Vitro 19 2005 299 334 10.1016/j.tiv.2004.06.011
13. K.M. Giacomini, S.M. Huang, D.J. Tweedie, L.Z. Benet, K.L. Brouwer, X. Chu, A. Dahlin, R. Evers, V. Fischer, K.M. Hillgren, K.A. Hoffmaster, T. Ishikawa, D. Keppler, R.B. Kim, C.A. Lee, M. Niemi, J.W. Polli, Y. Sugiyama, P.W. Swaan, J.A. Ware, S.H. Wright, S.W. Yee, M.J. Zamek-Gliszczynski, and L. Zhang Membrane transporters in drug development Nat. Rev. Drug Discov. 9 2010 215 236 10.1038/nrd3028
14. D. Groenendaal, J. Freijer, A. Rosier, D. de Mik, G. Nicholls, A. Hersey, A.D. Ayrton, M. Danhof, and E.C. de Lange Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics Eur. J. Pharm. Sci. 34 2008 149 163 10.1016/j.ejps.2008. 03.003
15. M. Guangli, and C. Yiyu Predicting Caco-2 permeability using support vector machine and chemistry development kit J. Pharm. Pharm. Sci. 9 2006 210 221
16. M. Gumbleton, and K.L. Audus Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier J. Pharm. Sci. 90 2001 1681 1698 10.1002/jps.1119
17. J.J. Hakkarainen, A.J. Jalkanen, T.M. Kääriäinen, P. Keski-Rahkonen, T. Venäläinen, J. Hokkanen, J. Mönkkönen, M. Suhonen, and M.M. Forsberg Comparison of in vitro cell models in predicting in vivo brain entry of drugs Int. J. Pharm. 402 2010 27 36 10.1016/j.ijpharm.2010. 09.016
18. D.K. Hansen, D.O. Scott, K.W. Otis, and S.M. Lunte Comparison of in vitro BBMEC permeability and in vivo CNS uptake by microdialysis sampling J. Pharm. Biomed. Anal. 27 2002 945 958 10.1016/S0731-7085(01)00542-8
19. A.J. Jalkanen, J.J. Hakkarainen, M. Lehtonen, T. Venäläinen, T.M. Kääriäinen, E. Jarho, M. Suhonen, and M.M. Forsberg Brain pharmacokinetics of two prolyl oligopeptidase inhibitors, JTP-4819 and KYP-2047, in the rat Basic Clin. Pharmacol. Toxicol 109 2011 443 451 10.1111/j.1742-7843. 2011.00747.x
20. E.M. Jarho, J.I. Venäläinen, J. Huuskonen, J.A. Christiaans, J.A. Garcia-Horsman, M.M. Forsberg, T. Järvinen, J. Gynther, P.T. Männistö, and E.A. Wallén A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors J. Med. Chem. 47 2004 5605 5607 10.1021/jm049503w
21. K. Jorga, B. Fotteler, P. Heizmann, and R. Gasser Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase Br. J. Clin. Pharmacol. 48 1999 513 520 10.1046/j.1365-2125.1999.00036.x
22. L.H. Krarup, I.T. Christensen, L. Hovgaard, and S. Frokjaer Predicting drug absorption from molecular surface properties based on molecular dynamics simulations Pharm. Res. 15 1998 972 978 10.1023/A:1011905522110
23. A.M. Lambeir Translational research on prolyl oligopeptidase inhibitors: the long road ahead Expert Opin. Ther. Pat. 21 2011 977 981 10.1517/13543776. 2011.587803
24. C. Li, T. Liu, X. Cui, A.S. Uss, and K.C. Cheng Development of in vitro pharmacokinetic screens using Caco-2, human hepatocyte, and Caco-2/human hepatocyte hybrid systems for the prediction of oral bioavailability in humans J. Biomol. Screen. 12 2007 1084 1091 10.1177/1087057107308892
25. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 46 2001 3 26 10.1016/S0169-409X(00)00129-0
26. X. Liu, B. Testa, and A. Fahr Lipophilicity and its relationship with passive drug permeation Pharm. Res. 28 2011 962 977 10.1007/s11095-010-0303-7
27. C. Lohmann, S. Hüwel, and H.J. Galla Predicting blood-brain barrier permeability of drugs: evaluation of different in vitro assays J. Drug Target. 10 2002 263 276 10.1080/10611860290031903
28. S. Lundquist, M. Renftel, J. Brillault, L. Fenart, R. Cecchelli, and M.P. Dehouck Prediction of drug transport through the blood-brain barrier in vivo: a comparison between two in vitro cell models Pharm. Res. 19 2002 976 981 10.1023/A:1016462205267
29. F.R. Luo, P.V. Paranjpe, A. Guo, E. Rubin, and P. Sinko Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1 Drug Metab. Dispos. 30 2002 763 770 10.1124/dmd.30.7.763
30. A. Mabondzo, M. Bottlaender, A.C. Guyot, K. Tsaouin, J.R. Deverre, and P.V. Balimane Validation of in vitro cell-based human blood-brain barrier model using clinical positron emission tomography radioligands to predict in vivo human brain penetration Mol. Pharm. 7 2010 1805 1815 10.1021/mp1002366
31. A.C. Moffat, M.D. Osselton, and B. Widdop Clarke's Analysis of Drugs and Poisons 2004 Pharmaceutical Press London
32. T. Österberg, and U. Norinder Prediction of polar surface area and drug transport processes using simple parameters and PLS statistics J. Chem. Inf. Comput. Sci. 40 2000 1408 1411 10.1021/ci000065l
33. P. Paixão, L.F. Gouveia, and J.A. Morais Prediction of the in vitro permeability determined in Caco-2 cells by using artificial neural networks Eur. J. Pharm. Sci. 41 2010 107 117 10.1016/j.ejps.2010.05.014
34. J.J. Palmgrén, J. Mönkkönen, E. Jukkola, S. Niva, and S. Auriola Characterization of Caco-2 cell monolayer drug transport properties by cassette dosing using UV/fluorescence HPLC Eur. J. Pharm. Biopharm. 57 2004 319 328 10.1016/j.ejpb.2003.10.016
35. W.M. Pardridge, D. Triguero, J. Yang, and P.A. Cancilla Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier J. Pharmacol. Exp. Ther. 253 1990 884 891
36. J.W. Polli, J.E. Humphreys, S.A. Wring, T.C. Burnette, K.C. Read, A. Hersey, D. Butina, L. Bertolotti, P. Pugnaghi, and C.J. Serabjit-Singh A comparison of Madin-Darby canine kidney cells and bovine brain endothelial cells as a blood-brain barrier screen in early drug discovery M. Balls, A.-M. van Zeller, M.E. Halder, Progress in the Reduction, Refinement and Replacement of Animal Experimentation 2000 Elsevier Science The Netherlands 271 289
37. A. Reichel The role of blood-brain barrier studies in the pharmaceutical industry Curr. Drug Metab. 7 2006 183 203 10.2174/138920006775541525
38. A. Saheki, T. Terasaki, I. Tamai, and A. Tsuji In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors Pharm. Res. 11 1994 305 311 10.1023/A:1018975928974
39. A. Seelig, R. Gottschlich, and R.M. Devant A method to determine the ability of drugs to diffuse through the blood-brain barrier Proc. Natl. Acad. Sci. U.S.A. 91 1994 68 72 10.1073/pnas.91.1.68
40. R.N. Shinde, K. Srikanth, and M.E. Sobhia Insights into the permeability of drugs and drug-likemolecules from MI-QSAR and HQSAR studies J. Mol. Model. 2011 10.1007/s00894-011-1121-5
41. P. Stenberg, U. Norinder, K. Luthman, and P. Artursson Experimental and computational screening models for the prediction of intestinal drug absorption J. Med. Chem. 44 2001 1927 1937 10.1021/jm001101a
42. K. Sugano, M. Kansy, P. Artursson, A. Avdeef, S. Bendels, L. Di, G.F. Ecker, B. Faller, H. Fischer, G. Gerebtzoff, H. Lennernaes, and F. Senner Coexistence of passive and carrier-mediated processes in drug transport Nat. Rev. Drug Discov. 9 2010 597 614 10.1038/nrd3187
43. S.G. Summerfield, K. Read, D.J. Begley, T. Obradovic, I.J. Hidalgo, S. Coggon, A.V. Lewis, R.A. Porter, and P. Jeffrey Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction J. Pharmacol. Exp. Ther. 322 2007 205 213 10.1124/jpet.107.121525
44. K. Toide, Y. Iwamoto, T. Fujiwara, and H. Abe JTP-4819: a novel prolyl endopeptidase inhibitor with potential as a cognitive enhancer J. Pharmacol. Exp. Ther. 274 1995 1370 1378
45. H. van de Waterbeemd, G. Camenisch, G. Folkers, and O.A. Raevsky Estimation of Caco-2 cell permeability using calculated molecular descriptors Quant. Struct. -Act. Relat. 15 1996 480 490 10.1002/qsar.19960150604
46. E.A. Wallén, J.A. Christiaans, S.M. Saario, M.M. Forsberg, J.I. Venäläinen, H.M. Paso, P.T. Männistö, and J. Gynther 4,- Phenylbutanoyl-2(S)-acylpyrrolidines and 4-phenylbutanoyl-L-prolyl-2(S)- acylpyrrolidines as prolyl oligopeptidase inhibitors Bioorg. Med. Chem. 10 2002 2199 2206 10.1016/S0968-0896(02)00061-5
47. Q. Wang, J.D. Rager, K. Weinstein, P.S. Kardos, G.L. Dobson, J. Li, and I.J. Hidalgo Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier Int. J. Pharm. 288 2005 349 359 10.1016/j.ijpharm.2004. 10.007